Skip to main content
SpringerLink
Log in

Sexualhormone

  • Chapter
Arzneiverordnungs-Report 2013

  • 1737 Accesses

Zusammenfassung

Sexualhormone werden zur Behandlung von Störungen der Sexualfunktion bei Mann und Frau eingesetzt. Sie dienen in erster Linie zur Substitution einer ungenügenden körpereigenen Hormonproduktion, aber auch zur Hemmung der Hormonproduktion durch Änderung der zentralen Regulationsvorgänge im Zwischenhirn und der Hypophyse. Neben vielen anderen Anwendungen sind Sexualhormone bei der Therapie von Sexualhormon-abhängigen Tumoren von Bedeutung.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 49.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • American College of Obstetricians and Gynecologists (2013): Committee opinion no. 556: Postmenopausal estrogen therapy: route of administration and risk of venous thromboembolism. Obstet Gynecol 121: 887–890.

    Google Scholar 

  • Arzneimittelkommission der deutschen Ärzteschaft (2003): Rote Hand Brief zur Hormontherapie im Klimakterium vom 09.12.2003. Im Internet: www.akdae.de/20/40/index.html.

  • Arzneimittelkommission der deutschen Ärzteschaft (2011): Risiko von venösen Thromboembolien bei Einnahme von Drospirenon-haltigen kombinierten oralen Kontrazeptiva (Yasmin®/Yasminelle®, Aida®, Yaz®, Petibelle®). Dtsch Ärztebl 108: A2442.

    Google Scholar 

  • Canonico M, Oger E, Plu-Bureau G, Conard J, Meyer G, Lévesque H, Trillot N, Barrellier MT, Wahl D, Emmerich J, Scarabin PY; Estrogen and Thromboembolism Risk (ESTHER) Study Group (2007): Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation 115: 840–845.

    Google Scholar 

  • Castelo-Branco C, Vicente JJ, Figueras F, Sanjuan A, Martinez de Osaba MJ, Casals E et al (2000): Comparative effects of estrogens plus androgens and tibolone on bone, lipid pattern and sexuality in postmenopausal women. Maturitas 34: 161–168.

    Article  PubMed  CAS  Google Scholar 

  • Cauley JA, Seeley DG, Ensrud K, Ettinger B, Black D, Cummings SR (1995): Estrogen replacement therapy and fractures in older women. Ann Intern Med 122: 9–16.

    Article  PubMed  CAS  Google Scholar 

  • Cheng L, Gulmezoglu AM, Oel CJ, Piaggio G, Ezcurra E, Look PF (2004): Interventions for emergency contraception.Cochrane Database Syst Rev. 2004; (3): CD001324.

    Google Scholar 

  • Chlebowski RT, Anderson GL, Gass M, Lane DS, Aragaki AK, Kuller LH, Manson JE, Stefanick ML, Ockene J, Sarto GE, Johnson KC, Wactawski-Wende J, Ravdin PM, Schenken R, Hendrix SL, Rajkovic A, Rohan TE, Yasmeen S, Prentice RL; WHI Investigators (2010): Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA 304: 1684–1692.

    Google Scholar 

  • Cogliano V, Grosse Y, Baan R, Straif K, Secretan B, El Ghissassi F; WHO International Agency for Research on Cancer (2005): Carcinogenicity of combined oestrogen-progestagen contraceptives and menopausal treatment. Lancet Oncol 6: 552–553.

    Google Scholar 

  • Collaborative Study Group on the Desogestrel-containing Progesteron-only Pill (1998): A double blind study comparing the contraceptive efficacy, acceptability and safety of two progesteron-only pills containing desogestrel 75 micrograms/day or levonorgestrel 30 micrograms/day. Eur J Contracept Reprod Health Care 3: 169–178.

    Google Scholar 

  • Creinin MD, Schlaff W, Archer DF, Wan L, Frezieres R, Thomas M, Rosenberg M, Higgins J (2006): Progesterone receptor modulator for emergency contraception: a randomized controlled trial. Obstet Gynecol 108: 1089–1097.

    Article  PubMed  CAS  Google Scholar 

  • Dinger JC, Heinemann LA, Kuhl-Habich D (2007): The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance Study on oral contraceptives based on 142,475 women-years of observation. Contraception 75: 344–354.

    Article  PubMed  CAS  Google Scholar 

  • Grodstein F, Manson JE, Colditz GA, Willett WC, Speizer FE, Stampfer MJ (2000): A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med 133: 933–1001.

    Article  PubMed  CAS  Google Scholar 

  • Gronich N, Lavi I, Rennert G (2011): Higher risk of venous thrombosis associated with drospirenone-containing oral contraceptives: a population-based cohort study. CMAJ 183: E1319–1325.

    Article  PubMed  Google Scholar 

  • Heiss G, Wallace R, Anderson GL, Aragaki A, Beresford SA, Brzyski R, Chlebowski RT, Gass M, LaCroix A, Manson JE, Prentice RL, Rossouw J, Stefanick ML; WHI Investigators (2008): Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin. JAMA 299: 1036–1045.

    Google Scholar 

  • Hilbert-Walter A, Büttner R, Sieber C, Bollheimer C (2012): Testosteron im Alter: ein Update. Dtsch Med Wochenschr 137: 2117–2122.

    Article  PubMed  CAS  Google Scholar 

  • Jick H, Jick SS, Gurewich V, Myers MW, Vasilakis C (1995): Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet 346: 1589–1593.

    Article  PubMed  CAS  Google Scholar 

  • Kemmeren JM, Algra A, Grobbee DE (2001): Third generation oral contraceptives and risk of venous thrombosis: meta-analysis. Brit Med J 323: 1–9.

    Article  Google Scholar 

  • LaCroix AZ, Chlebowski RT, Manson JE, Aragaki AK, Johnson KC, Martin L, Margolis KL, Stefanick ML, Brzyski R, Curb JD, Howard BV, Lewis CE, Wactawski-Wende J; WHI Investigators (2011): Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. JAMA 305: 1305–1314.

    Google Scholar 

  • Lidegaard Ø, Nielsen LH, Skovlund CW, Skjeldestad FE, Løkkegaard E (2011): Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001-9. BMJ 25;343: d6423.

    Article  Google Scholar 

  • Lidegaard O, Nielsen LH, Skovlund CW, Løkkegaard E (2012): Venous thrombosis in users of non-oral hormonal contraception: follow-up study, Denmark 2001-10. BMJ 344: e2990.

    Article  PubMed  Google Scholar 

  • Million Women Study Collaborators (2003): Breast cancer and hormone-replacement in the Million Women Study. Lancet 362: 419–427.

    Google Scholar 

  • Million Women Study Collaborators (2005): Endometrial cancer and hormone-replacement therapy in the Million Women Study. Lancet 365: 1543–1551.

    Google Scholar 

  • Million Women Study Collaborators (2007): Ovarian cancer and hormone replacement therapy in the Million Women Study. Lancet 369: 1703–1710.

    Google Scholar 

  • Modelska K, Cummings S (2002): Tibolone for postmenopausal women: systematic review of randomized trials. J Clin Endocrinol Metab. 87:16–23.

    Article  PubMed  CAS  Google Scholar 

  • NAMS Advisory Panel (2003): Amended report from the NAMS Advisory Panel on postmenopausal hormone therapy.Menopause 10: 6–12.

    Google Scholar 

  • Nelson HD (2004): Commonly used types of postmenopausal estrogen for treatment of hot flashes: scientific review. JAMA 291: 1610–1620.

    Article  PubMed  CAS  Google Scholar 

  • Oddsson K, Leifels-Fischer B, de Melo NR, Wiel-Masson D, Benedetto C, Verhoeven CH, Dieben TO (2005): Efficacy and safety of a contraceptive vaginal ring (NuvaRing) compared with a combined oral contraceptive: a 1-year randomized trial. Contraception 71: 176–182.

    Article  PubMed  CAS  Google Scholar 

  • Oelkers W, Foidart JM, Dombrovicz N, Welter A, Heithecker R (1995): Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the rennin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism. J Clin Endocrinol Metab 80: 1816–1821.

    Article  PubMed  CAS  Google Scholar 

  • Olié V, Canonico M, Scarabin PY (2010): Risk of venous thrombosis with oral versus transdermal estrogen therapy among postmenopausal women. Curr Opin Hematol 17: 457–463.

    Article  PubMed  Google Scholar 

  • Ravdin PM, Cronin KA, Howlader N, Berg CD, Chlebowski RT, Feuer EJ, Edwards BK, Berry DA (2007): The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med 356: 1670–1674.

    Article  PubMed  CAS  Google Scholar 

  • Royal College of General Practitioners Oral Contraception Study (1981): Further analysis of mortality in oral contraceptive users. Lancet I: 541–546.

    Google Scholar 

  • Schubert M, Minnemann T, Hubler D, Rouskova D, Christoph A, Oettel M, Ernst M, Mellinger U, Krone W, Jockenhövel F (2004): Intramuscular testosterone undecanoate: pharmacokinetic aspects of a novel testosterone formulation during long-term treatment of men with hypogonadism. J Clin Endocrinol Metab 89: 5429–5434.

    Article  PubMed  CAS  Google Scholar 

  • Spitzer WO, Lewis MA, Heinemann LAJ, Thorogood M, MacRae KD (1996): Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. Brit Med J 312: 83–88.

    Article  PubMed  CAS  Google Scholar 

  • Van Grootheest K, Vrieling T (2003): Thromboembolism associated with the new contraceptive Yasmin. BMJ 326: 257.

    Article  PubMed  Google Scholar 

  • World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception (1995): Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. Lancet 346: 1582–1588.

    Google Scholar 

  • Womens Health Initiative Steering Committee (2004): Effect of conjugated equine estrogen in postmenopausal women with hysterectomy. The Women’s Health Initiative randomized controlled trial. JAMA 291: 1701–1712.

    Google Scholar 

  • Writing Group for the Women’s Health Initiative (2002): Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women’s Health Initiative randomized controlled trial. JAMA 288: 321–333.

    Google Scholar 

  • Zbuk K, Anand SS (2012): Declining incidence of breast cancer after decreased use of hormone-replacement therapy: magnitude and time lags in different countries. J Epidemiol Community Health 66: 1–7.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Pharmakologisches Institut, Universität Heidelberg, Heidelberg, Im Neuenheimer Feld 366, 69120

    Prof. Dr. med. Ulrich Schwabe

Authors
  1. Prof. Dr. med. Ulrich Schwabe
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Pharmakologisches Institut, der Universität Heidelberg, Im Neuenheimer Feld 366, 69120, Heidelberg

    Ulrich Schwabe

  2. AOK NORDWEST Die Gesundheitskasse, Edisonstraße 70, 24145, Kiel

    Dieter Paffrath

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer-Verlag Berlin, Heidelberg

About this chapter

Cite this chapter

Schwabe, U. (2013). Sexualhormone. In: Schwabe, U., Paffrath, D. (eds) Arzneiverordnungs-Report 2013. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-37124-0_42

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-37124-0_42

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-37123-3

  • Online ISBN: 978-3-642-37124-0

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation